Health and Healthcare
Is Amgen Overpaying for Celgene's Psoriasis Treatment?
Published:
Last Updated:
Both Amgen Inc. (NASDAQ: AMGN) and Celgene Corp. (NASDAQ: CELG) shares made a handy gain on Monday after it was announced that the companies had made an agreement in relation to Celgene’s merger with Bristol-Myers Squibb Co. (NYSE: BMY).
Essentially, Amgen is buying worldwide rights to Otezla, Celgene’s treatment for psoriasis and psoriatic arthritis, for a total of $13.4 billion in cash.
Sales of Otezla in 2018 were $1.6 billion driven by strong volume growth. Amgen has stated previously that it will focus on medicines that can deliver sustained, long-term volume-driven growth and the company believes there is a significant opportunity to grow Otezla through global expansion and new indications, with expectations for Otezla to realize at least low double-digit sales growth, on average, over the next five years.
The closing of the acquisition is contingent on Bristol-Myers Squibb entering into a consent decree with the Federal Trade Commission in connection with the pending Celgene merger, The transaction is expected to close by the end of 2019.
Some might argue against this acquisition by Amgen as the company is already saddled with debt. A quick look at its balance sheet reveals that the firm has roughly $29.5 billion in long-term debt and only about $6.95 billion in cash and cash equivalents.
Robert A. Bradway, board chair and chief executive at Amgen, commented:
The acquisition of Otezla offers a unique opportunity for Amgen to provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel and Amgevita brands. We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions.
Shares of Amgen were last seen up about 3% at $204.94, in a 52-week range of $166.30 to $211.90. The consensus price target is $209.45.
Celgene shares were last seen up nearly 3% at $96.64, in a 52-week range of $58.59 to $98.97. The consensus price target is $96.80.
Bristol-Myers recently traded up about 3% at $47.88 a share, in a 52-week range of $42.48 to $63.69.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
